Sugi Predict

Sugi Predict / Compounds / SCHEMBL85933

SCHEMBL85933

SCHEMBL85933

CNC(=O)C1CCCC(=O)N1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP9 P14780 7/20 0.43
▸ MMP1 P03956 5/20 0.43
▸ ADAM17 P78536 4/20 0.43
▸ HDAC3 O15379 7/20 0.42
▸ HDAC11 Q96DB2 7/20 0.42
▸ HDAC6 Q9UBN7 7/20 0.42
▸ HDAC1 Q13547 6/20 0.42
▸ HDAC2 Q92769 6/20 0.42
▸ HDAC10 Q969S8 6/20 0.42
▸ HDAC8 Q9BY41 6/20 0.42
▸ ABL1 P00519 1/20 0.41
▸ NCOR2 Q9Y618 1/20 0.40
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MMP3 P08254 4/20 0.39
▸ MMP2 P08253 2/20 0.39
▸ MMP8 P22894 2/20 0.39
▸ HDAC4 P56524 1/20 0.39
▸ HDAC7 Q8WUI4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13451733 0.89 SMN1; SMN2 (0.48) MMP9MMP1ADAM17MEN1KMT2A
SCHEMBL85699 0.89 SMN1; SMN2 (0.48) MMP9MMP1ADAM17MEN1KMT2A
SCHEMBL10705064 0.81 HDAC3 (0.42) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL10176030 0.81 HDAC3 (0.42) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL8426408 0.79 HDAC3 (0.36) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL2143334 0.79 HDAC3 (0.36) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL15347243 0.78 HDAC3 (0.38) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL5026447 0.78 KMT2A (0.42) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL4939718 0.78 KMT2A (0.42) HDAC3HDAC11HDAC6HDAC1HDAC2
SCHEMBL4939720 0.78 KMT2A (0.42) HDAC3HDAC11HDAC6HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4522596-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X Discovery Limited (GB) 2025-03-19 — — EP disclosed
WO-2023218203-A1 DIHYDROINDENE DERIVATIVES AS MALT1 INHIBITORS C4X DISCOVERY LIMITED (GB) 2023-11-16 — — WO disclosed
US-9656991-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2017-05-23 — — US disclosed
US-9650362-B2 Inhibitors PROBIODRUG AG (DE) 2017-05-16 — — US disclosed
US-9512082-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2016-12-06 — — US disclosed
US-9512115-B2 Inhibitors PROBIODRUG AG (DE) 2016-12-06 — — US disclosed
US-9462793-B2 Mouse carrying a knock-out mutation of the Qpct-gene PROBIODRUG AG (DE) 2016-10-11 — — US disclosed
US-9277737-B2 Mouse models carrying a knock-out mutation of the QPCTL-gene PROBIODRUG AG (DE) 2016-03-08 — — US disclosed
US-20160031869-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2016-02-04 — — US disclosed
US-9181233-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2015-11-10 — — US disclosed
US-20080234313-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2008-09-25 — — US disclosed
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-09-11 — — US disclosed
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-04 — — US disclosed
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-08-28 — — US disclosed
US-20080200567-A1 IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS PROBIODRUG AG (DE) 2008-08-21 — — US disclosed
US-20080153892-A1 Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-06-26 — — US disclosed
US-7381537-B2 Use of inhibitors of glutaminyl cyclases for treatment and prevention of disease PROBIODRUG AG (DE) 2008-06-03 — — US disclosed
US-7371871-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2008-05-13 — — US disclosed
US-7304086-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2007-12-04 — — US disclosed
US-20070191366-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES PROBIODRUG AG (DE) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191366-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES GLS, QPCT, GLS2 MMP9 3888/4885MMP1 4081/4885ADAM17 2281/4885
US-20080153892-A1 Inhibitors of Glutaminyl Cyclase GLS2, GLS, GLUL MMP9 3745/4885MMP1 4663/4885ADAM17 3299/4885
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL MMP9 4150/4885MMP1 4176/4885ADAM17 3611/4885
US-20160031869-A1 NOVEL INHIBITORS GLS, GLUL, QPCT MMP9 2891/4885MMP1 3641/4885ADAM17 2886/4885
US-20080200567-A1 IN VIVO SCREENING MODELS FOR TREATMENT OF ALZHEIMER'S DISEASE AND OTHER QPCT-RELATED DISORDERS QPCT, PCYT1A, PSEN2 MMP9 3868/4885MMP1 3352/4885ADAM17 3090/4885
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL MMP9 4246/4885MMP1 4099/4885ADAM17 4527/4885
US-20080234313-A1 NOVEL INHIBITORS SF3A1, HBS1L, SF3A3 MMP9 2322/4885MMP1 1621/4885ADAM17 3748/4885
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL MMP9 3743/4885MMP1 3735/4885ADAM17 4266/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.